COCP Cocrystal Pharma Inc.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Cocrystal Pharma Inc.

Peers

Recent Analyst Ratings for Cocrystal Pharma Inc.

Cocrystal Pharma Inc. SEC Filings

Cocrystal Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

Cocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Cocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Cocrystal Pharma Inc.

Cocrystal Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Cocrystal Pharma Inc.

SEC Form DEF 14A filed by Cocrystal Pharma Inc.

SEC Form PRE 14A filed by Cocrystal Pharma Inc.

Cocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Cocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Cocrystal Pharma Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Kornberg Roger D. was granted 28,109 shares (SEC Form 4)

Director Frost Phillip Md Et Al was granted 27,100 shares (SEC Form 4)

President and Co-CEO Lee Sam was granted 40,000 shares, increasing direct ownership by 110% to 76,355 units (SEC Form 4)

Co-CEO and CFO Martin James Joseph was granted 40,000 shares, increasing direct ownership by 7,030% to 40,569 units (SEC Form 4)

Director Pfenniger Richard C Jr was granted 8,067 shares, increasing direct ownership by 242% to 11,400 units (SEC Form 4)

Director Rubin Steven D was granted 18,957 shares, increasing direct ownership by 0.72% to 2,660,242 units (SEC Form 4)

Director Hassan Fred was granted 8,067 shares, increasing direct ownership by 0.79% to 1,023,296 units (SEC Form 4)

Director Japour Anthony J was granted 14,924 shares (SEC Form 4)

SEC Form 4 filed by Frost Phillip Md Et Al

SEC Form 4 filed by Martin James Joseph